Pfizer (PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts PFE Hot Sheet
Price: $30.03 -1.28%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.7%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.9%
Revenue Growth %: -4.7%
Join SI Premium – FREE
Pfizer (NYSE: PFE) Sees Approval of MRNA Flu Vaccine in 2024 - Bloomberg, Citing Presentation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
- FS Bancorp appoints Matthew Mullet to its board of directors
- Vital Farms pilots free-range eggs at Target stores under $5
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
